Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management.

Stearns LJ, Hinnenthal JA, Hammond K, Berryman E, Janjan NA.

Neuromodulation. 2016 Feb;19(2):196-205. doi: 10.1111/ner.12384. Epub 2016 Jan 27.

2.

Adult cancer pain.

Swarm RA, Abernethy AP, Anghelescu DL, Benedetti C, Buga S, Cleeland C, Deleon-Casasola OA, Eilers JG, Ferrell B, Green M, Janjan NA, Kamdar MM, Levy MH, Lynch M, McDowell RM, Moryl N, Nesbit SA, Paice JA, Rabow MW, Syrjala KL, Urba SG, Weinstein SM, Dwyer M, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Aug;11(8):992-1022.

3.

Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force.

Cleeland CS, Sloan JA, Cella D, Chen C, Dueck AC, Janjan NA, Liepa AM, Mallick R, O'Mara A, Pearson JD, Torigoe Y, Wang XS, Williams LA, Woodruff JF; CPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force.

Cancer. 2013 Jan 15;119(2):411-20. doi: 10.1002/cncr.27744. Epub 2012 Aug 28.

4.

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH; American Society of Clinical Oncology.

J Clin Oncol. 2011 Mar 20;29(9):1221-7. doi: 10.1200/JCO.2010.32.5209. Epub 2011 Feb 22. Erratum in: J Clin Oncol. 2011 Jun 1;29(16):2293.

PMID:
21343561
5.

Adult cancer pain.

Swarm R, Abernethy AP, Anghelescu DL, Benedetti C, Blinderman CD, Boston B, Cleeland C, Coyle N, Deleon-Casasola OA, Eilers JG, Ferrell B, Janjan NA, Karver SB, Levy MH, Lynch M, Moryl N, Murphy BA, Nesbit SA, Oakes L, Obbens EA, Paice JA, Rabow MW, Syrjala KL, Urba S, Weinstein SM; NCCN Adult Cancer Pain.

J Natl Compr Canc Netw. 2010 Sep;8(9):1046-86. No abstract available.

6.

Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards.

Cleeland CS, Sloan JA; ASCPRO Organizing Group.

J Pain Symptom Manage. 2010 Jun;39(6):1077-85. doi: 10.1016/j.jpainsymman.2009.05.025. Review.

PMID:
20538189
7.

American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy.

Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, Mehta MP, Ryu S, Steinberg M, Timmerman R, Welsh JS, Rosenthal SA; American Society for Therapeutic Radiology and Oncology; American College of Radiology.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):326-32. doi: 10.1016/j.ijrobp.2009.09.042. No abstract available.

PMID:
20117285
8.

Long-term quality of life after radiotherapy for the treatment of anal cancer.

Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, Delclos ME, Krishnan S, Janjan NA, Crane CH.

Cancer. 2010 Feb 15;116(4):822-9. doi: 10.1002/cncr.24906.

9.

Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.

Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA.

Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):824-30. doi: 10.1016/j.ijrobp.2009.02.037. Epub 2009 May 21.

PMID:
19464823
10.

Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.

Park HC, Janjan NA, Mendoza TR, Lin EH, Vadhan-Raj S, Hundal M, Zhang Y, Delclos ME, Crane CH, Das P, Wang XS, Cleeland CS, Krishnan S.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):775-81. doi: 10.1016/j.ijrobp.2008.11.027. Epub 2009 Feb 21.

11.

Pain and suffering during cancer therapy: continued sins of omission.

Janjan NA, Cleeland CS.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):6-8. doi: 10.1016/j.ijrobp.2008.05.048. No abstract available.

PMID:
18722257
12.

Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery.

Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S.

Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):167-72. doi: 10.1016/j.ijrobp.2007.09.019.

PMID:
18406886
13.

Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer.

Yu TK, Bhosale PR, Crane CH, Iyer RB, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Das P.

Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1175-80. doi: 10.1016/j.ijrobp.2007.11.018. Epub 2008 Jan 22.

14.

Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy.

Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW, Pisters PW, Ajani JA, Crane CH.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):741-7. doi: 10.1016/j.ijrobp.2007.10.030. Epub 2007 Dec 31.

15.

Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.

Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW.

Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):735-43. Epub 2007 Nov 5.

PMID:
17980502
16.

Adult cancer pain.

Swarm R, Anghelescu DL, Benedetti C, Boston B, Cleeland C, Coyle N, Deleon-Casasola OA, Eidelman A, Eilers JG, Ferrell B, Grossman SA, Janjan NA, Levy MH, Lynch M, Montana GS, Nesbit S, Oakes L, Obbens EA, Paice J, Syrjala KL, Urba S, Weinstein SM; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2007 Sep;5(8):726-51. No abstract available.

PMID:
17927930
17.

Clinical benefit of palliative radiation therapy in advanced gastric cancer.

Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S.

Acta Oncol. 2008;47(3):421-7.

PMID:
17899453
18.

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.

Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH.

Cancer. 2007 Jul 1;110(1):47-55.

19.

Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.

Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH.

Cancer. 2007 May 1;109(9):1750-5.

20.

Predictors and patterns of recurrence after definitive chemoradiation for anal cancer.

Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800. Epub 2007 Mar 26.

PMID:
17379452
21.

Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer.

Bedi M, Das P, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C, Wolff RA, Janjan NA, Krishnan S, Crane CH.

Gastrointest Cancer Res. 2007 Mar;1(2):44-8.

22.

Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases.

Krishnan S, Lin EH, Gunn GB, Chandra A, Beddar AS, Briere TM, Das P, Delclos ME, Janjan NA, Crane CH.

Am J Clin Oncol. 2006 Dec;29(6):562-7.

PMID:
17148992
23.

Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.

Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Palla S, Guha S, Varadhachary G, Evans DB, Wolff RA, Crane CH.

Cancer. 2006 Dec 1;107(11):2589-96.

24.

Concurrent capecitabine and upper abdominal radiation therapy is well tolerated.

Das P, Wolff RA, Abbruzzese JL, Varadhachary GR, Evans DB, Vauthey JN, Baschnagel A, Delclos ME, Krishnan S, Janjan NA, Crane CH.

Radiat Oncol. 2006 Oct 24;1:41.

25.

Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.

Das P, Lin EH, Bhatia S, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Delclos ME, Krishnan S, Janjan NA, Crane CH.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1378-83. Epub 2006 Oct 23.

PMID:
17056196
26.

Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.

Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EH.

Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):762-71.

PMID:
17011451
27.

Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.

Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Levy LB, Ellis LM, Crane CH.

Am J Clin Oncol. 2006 Jun;29(3):219-24.

PMID:
16755173
28.

Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.

Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M.

J Natl Cancer Inst. 2005 Jun 1;97(11):798-804.

PMID:
15928300
29.

Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.

Bonnen M, Crane C, Vauthey JN, Skibber J, Delclos ME, Rodriguez-Bigas M, Hoff PM, Lin E, Eng C, Wong A, Janjan NA, Feig BW.

Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1098-105.

PMID:
15519780
30.

American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy.

Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, Welsh J, Mehta M, Larson DA, Janjan NA; American Society for Therapeutic Radiology and Oncology; American College of Radiology.

Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1026-32. No abstract available.

PMID:
15519771
31.

Combined-modality therapy for gastric cancer.

Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA.

Semin Surg Oncol. 2003;21(4):223-7. Review.

PMID:
14648779
32.

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S; American Society of Clinical Oncology.

J Clin Oncol. 2003 Nov 1;21(21):4042-57. Epub 2003 Sep 8. Erratum in: J Clin Oncol. 2004 Apr 1;22(7):1351. Dosage error in article text.

PMID:
12963702
33.

The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer.

Crane CH, Skibber JM, Birnbaum EH, Feig BW, Singh AK, Delclos ME, Lin EH, Fleshman JW, Thames HD, Kodner IJ, Lockett MA, Picus J, Phan T, Chandra A, Janjan NA, Read TE, Myerson RJ.

Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):84-9.

PMID:
12909219
34.

Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.

Crane CH, Mason K, Janjan NA, Milas L.

Am J Clin Oncol. 2003 Aug;26(4):S81-4. Review.

PMID:
12902862
35.

Chemoradiation for adenocarcinoma of the anus.

Papagikos M, Crane CH, Skibber J, Janjan NA, Feig B, Rodriguez-Bigas MA, Hung A, Wolff RA, Delclos M, Lin E, Cleary K.

Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):669-78.

PMID:
12573754
36.

Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma.

Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA, Rodriguez-Bigas MA, Wolff RA, Ellis LM, Delclos ME, Lin EH, Janjan NA.

Cancer. 2003 Jan 15;97(2):517-24.

37.

Pain and quality of life after treatment in patients with locally recurrent rectal cancer.

Esnaola NF, Cantor SB, Johnson ML, Mirza AN, Miller AR, Curley SA, Crane CH, Cleeland CS, Janjan NA, Skibber JM.

J Clin Oncol. 2002 Nov 1;20(21):4361-7.

PMID:
12409336
38.

Preoperative chemoradiation for locally advanced rectal cancer: emerging treatment strategies.

Crane CH, Janjan NA, Mason K, Milas L.

Oncology (Williston Park). 2002 May;16(5 Suppl 5):39-44. Review.

39.

Limitations of conventional doses of chemoradiation for unresectable biliary cancer.

Crane CH, Macdonald KO, Vauthey JN, Yehuda P, Brown T, Curley S, Wong A, Delclos M, Charnsangavej C, Janjan NA.

Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):969-74.

PMID:
12095564
40.

Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome.

Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, Lenzi R, Vauthey JN, Lee JE, Abbruzzese JL, Evans DB.

J Clin Oncol. 2002 May 15;20(10):2537-44.

PMID:
12011133

Supplemental Content

Loading ...
Support Center